Precigen scores FDA nod for first-ever treatment for HPV-related disorder
For the first time, the FDA has
Related Articles
Wat blijft
Wat blijft als we er niet meer zijn? Wat Blijft is een radioprogramma en een podcast van Omroep HUMAN. In de podcastserie Wat blijft volgen…
Opinion | Sowing doubt about mRNA vaccines betrays Trump’s legacy
The president deserves an NIH director who champions science rather than dangerous nonsense.
E is for Epi | Ellie Murray, ScD | Substack
Making sense of the science of public health. Click to read E is for Epi, by Ellie Murray, ScD, a Substack publication with hundreds of…
V116 Well-Tolerated With Broad Immune Responses in Pneumococcal Vaccine-Naïve Older Adults
In a phase 3 trial, V116 demonstrated significant immunogenicity in older adults who had not before received a pneumococcal vaccination.
The Consequences of Doxycycline Postexposure Prophylaxis
Doxycycline postexposure prophylaxis is associated with emerging tetracycline resistance in Neisseria gonorrhoeae and commensal organisms, highlighting the need for cautious, targeted use.
Meet the IAS change makers
IAS change makers are recipients of our grant, fellowship or mentorship opportunities. They are the next generation of HIV researchers, advocates and healthcare providers taking…
Why one doctor says we’re ‘walking blind’ in the mpox emergency
A year ago, on August 14, 2024, the World Health Organization declared mpox a Public Health Emergency of International Concern. Why are health experts so…
TWiV 1244: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses Vijay Prasad’s return to the FDA, revoking of COVID vaccine authorization for young children,…
Members’ Area
The IAS Members’ Area is a platform that allows you to contact other IAS Members, download knowledge toolkits on the latest in HIV science, and…